<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124210</url>
  </required_header>
  <id_info>
    <org_study_id>215226</org_study_id>
    <nct_id>NCT05124210</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19</brief_title>
  <acronym>COMET-PACE</acronym>
  <official_title>An Open-label, Non-comparator, Multicenter Study to Describe the Pharmacokinetics (PK), Pharmacodynamics (PD; Viral Load) and Safety Following a Single Intravenous or Intramuscular Dose of Sotrovimab in Pediatric Participants With Mild to Moderate COVID-19 at High Risk of Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety&#xD;
      of sotrovimab in pediatric participants from birth to less than (&lt;)18 years old with&#xD;
      mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 3, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight-adjusted serum clearance of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to infinity (AUC[0-inf]) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T1/2) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability (F) following administration of sotrovimab</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs), serious adverse events (SAEs), and AEs of special interest (AESI)</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with progression of COVID-19 through Day 29</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Progression of COVID-19 is defined as need for attended medical visit (includes visit to a hospital emergency room for management of illness or hospitalization for acute management of illness) or escalation to higher level of medical care or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with development of severe and/or critical respiratory COVID-19 through Day 29</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Severe and/or critical respiratory COVID-19 as manifested by requirement for supplemental oxygen through Day 29. For participants who require oxygen or respiratory support for premorbid conditions, disease progression is defined as any sustained (greater than [&gt;]24 hours) increase in the level or method of oxygen support required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in viral load in nasal secretions measured by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)</measure>
    <time_frame>Baseline, at Day 5, Day 8 and Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort A: Participants receiving sotrovimab via Intravenous administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Participants receiving sotrovimab via Intramuscular administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotrovimab</intervention_name>
    <description>Sotrovimab will be administered.</description>
    <arm_group_label>Cohort A: Participants receiving sotrovimab via Intravenous administration</arm_group_label>
    <arm_group_label>Cohort B: Participants receiving sotrovimab via Intramuscular administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Participant must be 32 weeks estimated gestational age (EGA), day of life (DOL) 0 to&#xD;
             &lt;18 years of age inclusive, at either the time of participant's signed assent (if&#xD;
             age-appropriate) or parent(s)/legally authorized representative signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Participants with mild-moderate COVID-19.&#xD;
&#xD;
          -  Participants at risk of disease progression with at least one of the following&#xD;
             criteria: Age &lt;1 year; Diabetes mellitus; Genetic or metabolic diseases; Obesity );&#xD;
             Cardiovascular disease; Sickle cell disease; Pulmonary disease; Neurologic disease;&#xD;
             Immunosuppressed ; Baseline medical complexity (gastrostomy- or&#xD;
             jejunostomy-dependence, parenteral nutrition dependence, tracheostomy-dependence,&#xD;
             Baseline oxygen requirement, use of Continuous positive airway pressure [CPAP]/&#xD;
             Bilevel positive airway pressure [BiPAP]/ventilator support).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding.&#xD;
&#xD;
          -  Participant is currently hospitalized, or judged by the investigator as likely to&#xD;
             require hospitalization in the next 24 hours, due to severe or critical COVID-19.&#xD;
&#xD;
          -  Multisystem inflammatory syndrome in children (MIS-C).&#xD;
&#xD;
          -  Prior, current, or planned future use of any of the following treatments during the&#xD;
             study period: COVID-19 convalescent plasma, Monoclonal antibodies (mAbs) against&#xD;
             Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (for example [e.g.],&#xD;
             casirivimab/imdevimab), intravenous immunoglobulin (IVIG) for any indication, or&#xD;
             dexamethasone specifically for treatment of COVID-19.&#xD;
&#xD;
          -  Current use of COVID-19 treatment (authorized, approved, or investigational).&#xD;
&#xD;
          -  The following exclusions related to use of an authorized or approved vaccine for&#xD;
             SARS-CoV-2 are applicable:&#xD;
&#xD;
               1. Receipt of any authorized or approved vaccine for SARS-CoV-2 within 48 hours&#xD;
                  prior to dosing.&#xD;
&#xD;
               2. Planned use of any authorized or approved vaccine for SARS-CoV-2 within 90 days&#xD;
                  of study drug administration per current Centers for Disease Control and&#xD;
                  Prevention (CDC) recommendations.&#xD;
&#xD;
          -  Receipt of any non-SARS-CoV-2 vaccines within 14 days (for non-live vaccines) or 28&#xD;
             days (for live vaccine) of screening.&#xD;
&#xD;
          -  Currently enrolled in another clinical study.&#xD;
&#xD;
          -  Infants &lt;24 weeks of age: maternal receipt of IVIG, SARS-CoV-2-directed convalescent&#xD;
             plasma or SARS-CoV-2-directed mAb(s) within 3 months prior to birth or within 5&#xD;
             half-lives of the investigational product (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Sotrovimab</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Intramuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

